Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Tools & Technology › PCR › BARDA Awards DxTerity Diagnostics $150M Contract for Radiation Exposure Test

BARDA Awards DxTerity Diagnostics $150M Contract for Radiation Exposure Test

Oct 05, 2016

NEW YORK (GenomeWeb) — The US Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) has awarded a contract worth up to $150 million to DxTerity Diagnostics to develop and deliver its REDI-Dx biodosimetry test for radiation exposure, the firm announced today.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
15
Featured Webinar

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

What's Popular?

In PCR

  1. FDA Issues New Guidance for SARS-CoV-2 Pooled Sample Testing

  2. FDA Letter Warns About False-Positive Results From Becton Dickinson SARS-CoV-2 Test

  3. BioMérieux Reports 62 Percent BioFire FilmArray Sales Growth in Preliminary Q2 Release

  4. Amid Interest Generated by Coronavirus Testing, IPO Window Open for Dx Firms in 2020

    Premium

  5. Laboratorio Clinico Toledo, Assure Tech Coronavirus Tests Get Emergency Use Authorizations

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.